Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mesoblast Limited
  6. News
  7. Press Releases
    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société MESOBLAST LIMITED
11/26MESOBLAST : AND OAKTREE CAPITAL ENTER INTO REFINANCING AND EXPANSION OF SENIOR DEBT FACILI..
PU
11/23Operational Highlights and Financial Results for the Period Ended September 30, 2021
GL
11/23Operational Highlights and Financial Results for the Period Ended September 30, 2021
GL
11/23MESOBLAST : First Quarter Results Presentation
PU
11/23MESOBLAST : MSB Q1 Financial Results and Operational Highlights
PU
11/23Mesoblast Corporate Update and Financial Results Webcast
GL
11/21Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facil..
GL
11/21MESOBLAST : Proposed issue of securities - MSB
PU
11/16MESOBLAST : LATE BREAKING PRESENTATION AT AMERICAN HEART ASSOCIATION ANNUAL MEETING OF LAN..
PU
11/14Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Pha..
GL
11/14Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Pha..
GL
11/09Corporate Governance Council Principles and Recommendations - Form 6-K
PU
11/04APPENDIX 4C QUARTERLY ACTIVITY REPORT - Form 6-K
PU
10/28Appendix 4C Quarterly Activity Report
GL
10/28Appendix 4C Quarterly Activity Report
GL
10/19MESOBLAST : Appendix 3G Notification of issue, conversion or payment up of unquoted equity..
PU
10/18MESOBLAST : Remestemcel-l improves survival of children with biomarkers for highest mortal..
AQ
10/08MESOBLAST : REXLEMESTROCEL-L PHASE 3 TRIAL RESULTS IN CHRONIC HEART FAILURE SELECTED AS LA..
PU
10/06MESOBLAST : Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as La..
GL
10/01MESOBLAST : Management Team
PU
09/01MESOBLAST : OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE YEAR ENDED JUNE 30, 2021 ..
PU
08/30Operational Highlights and Financial Results for the Year Ended June 30, 2021
GL
08/30MESOBLAST : Corporate Update and Financial Results Webcast
AQ
08/28MESOBLAST : Management Team
PU
08/03MESOBLAST : APPENDIX 4C QUARTERLY ACTIVITY REPORT (Form 6-K)
PU
08/02MESOBLAST : Operational and Financial Highlights for Quarter Ended June 30, 2021
AQ
07/30MESOBLAST LIMITED : - Release of shares from voluntary escrow
AQ
07/29Appendix 4C Quarterly Activity Report
GL
07/21MESOBLAST : PRESENTS RESPIRATORY FUNCTION RESULTS OF COVID-19 ARDS TRIAL AT PULMONARY DISE..
PU
07/18Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT ..
GL
07/15Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Dis..
GL
07/02MESOBLAST : PROVIDES UPDATE ON PROGRAM FOR CHRONIC LOW BACK PAIN DUE TO DEGENERATIVE DISC ..
PU
06/30Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc..
GL
06/04MESOBLAST : OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, 20..
PU
06/02Operational Highlights and Financial Results for the Period Ended March 31, 2021
GL
06/02MESOBLAST : Third Quarter Results Presentation
PU
06/02Mesoblast Corporate Update and Financial Results Webcast
GL
06/02MESOBLAST : Corporate Update and Financial Results Webcast
AQ
05/27MESOBLAST : IMPROVED OUTCOMES IN INFLAMMATORY LUNG DISEASE WITH REMESTEMCEL-L PUBLISHED IN..
PU
05/25MESOBLAST : Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in..
AQ
05/03REMESTEMCEL-L REDUCES MORTALITY IN P : Topline 60-day results from randomized controlled t..
PU
04/29Appendix 4C Quarterly Activity Report
GL
04/29REMESTEMCEL-L REDUCES MORTALITY IN P : Topline 60-Day Results From Randomized Controlled T..
GL
04/29Mesoblast Corporate Update
GL
04/05MESOBLAST : Director's Interest Notice - Appendix 3X
PU
03/30MESOBLAST : Operational Highlights and Upcoming Milestones
PU
03/29MESOBLAST : Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Develop..
AQ
03/28MESOBLAST : Director Appointment/Resignation
PU
03/14MESOBLAST : Prospectus for Warrants in Connection with US$110M Raise
PU
03/10MESOBLAST LIMITED : - MSB Closes US$110M Raise Led By US Strategic Investor Group
AQ
03/10MESOBLAST LIMITED : - Notice under Section 708A(5)(e) of the Corporations Act 2001
AQ
03/08Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group
GL
03/08MESOBLAST : MSB Closes US$110M Raise Led By US Strategic Investor Group
PU
03/08MESOBLAST : Cleansing Notice and Appendix 2A
PU
03/04MESOBLAST LIMITED : - Notice under Section 708A(5)(e) of the Corporations Act 2001
AQ
03/02MESOBLAST : Completes US$110/A$138 Million Financing Led by US Strategic Investor Group
AQ
03/01MESOBLAST : Proposed issue of Securities - MSB
PU
03/01MESOBLAST : Raises US$110M Led By US Strategic Investor Group
PU
03/01MESOBLAST LIMITED : - Request for trading halt for Mesoblast Limited :
AQ
02/18MESOBLAST LIMITED : - Positive Outcomes of First Children Treated With Remestemcel-L for M..
AQ
02/17Positive Outcomes of First Children Treated With Remestemcel-L for Multisystem Inflamma..
GL
02/12MESOBLAST : Management Team
PU
02/10Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic ..
GL
02/10MESOBLAST : Phase 3 Chronic Low Back Pain Results
PU
02/10MESOBLAST : Corporate Update Webcast
PU
02/10Mesoblast Corporate Update
GL
01/28Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
GL
01/28MESOBLAST : Appendix 4C Quarterly Activity Report
PU
01/11Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conferenc..
GL
01/11MESOBLAST LIMITED : - Single Dose of Rexlemestrocel-L Provides Substantial and Durable Red..
AQ
01/10Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Att..
GL
2020Mesoblast Webcast – Update on COVID-19 ARDS Trial
GL
2020MESOBLAST : Webcast
PU
2020Mesoblast Update on COVID-19 ARDS Trial
GL
2020MESOBLAST LIMITED : - Request for trading halt for Mesoblast Limited :
AQ
1  2  3  4  5  6  7  8Next
Upcoming event on MESOBLAST LIMITED
11/28/21
Upcoming sector events